[1]方 敏.硼替佐米联合地塞米松与沙利度胺对多发性骨髓瘤伴肾功能不全患者骨代谢调节因子、免疫及肾功能的影响[J].医学信息,2022,35(05):165-167.[doi:10.3969/j.issn.1006-1959.2022.05.044]
　FANG Min.Effects of Bortezomib Combined with Dexamethasone and Thalidomide on Bone Metabolic Regulatory Factors,Immunity and Renal Function in Multiple Myeloma Patients with Renal Insufficiency[J].Medical Information,2022,35(05):165-167.[doi:10.3969/j.issn.1006-1959.2022.05.044]
点击复制

硼替佐米联合地塞米松与沙利度胺对多发性骨髓瘤伴肾功能不全患者骨代谢调节因子、免疫及肾功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年05期
页码:
165-167
栏目:
药物与临床
出版日期:
2022-03-01

文章信息/Info

Title:
Effects of Bortezomib Combined with Dexamethasone and Thalidomide on Bone Metabolic Regulatory Factors,Immunity and Renal Function in Multiple Myeloma Patients with Renal Insufficiency
文章编号:
1006-1959（2022）05-0165-03
作者:
方 敏
（佳木斯市中心医院血液内科，黑龙江 佳木斯 154002）
Author(s):
FANG Min
(Department of Hematology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
硼替佐米; 地塞米松; 沙利度胺; 多发性骨髓瘤; 骨代谢调节因子
Keywords:
Bortezomib; Dexamethasone; Thalidomide; Multiple myeloma; Bone metabolic regulators
分类号:
R739.42
DOI:
10.3969/j.issn.1006-1959.2022.05.044
文献标志码:
A
摘要:
目的 探讨硼替佐米联合地塞米松与沙利度胺对多发性骨髓瘤伴肾功能不全患者的治疗疗效。方法 选取2019年6月-2021年6月在我院治疗的84例多发性骨髓瘤伴肾功能不全患者为研究对象，采用随机数字表法分为对照组和观察组，各42例。对照组采用环磷酰胺、地塞米松和沙利度胺方案治疗，观察组给予硼替佐米、地塞米松和沙利度胺方案治疗。比较两组临床治疗总有效率、骨代谢调节因子水平、免疫功能指标、肾功能指标以及不良反应发生情况。结果 观察组治疗总有效率为95.24%，高于对照组的83.33%（P＜0.05）；两组核因子KB受体活化因子配体（RANKL）、抗酒石酸酸性磷酸酶及碱性磷酸酶（TRACP-5b）均低于治疗前，且观察组低于对照组（P＜0.05）；CD3+、CD4+、CD4+/CD8+均高于治疗前，且观察组高于对照组（P＜0.05）；两组血肌酐（Scr）、尿素氮（BUN）均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为9.52%，低于对照组的21.43%（P＜0.05）。结论 硼替佐米联合地塞米松与沙利度胺治疗多发性骨髓瘤伴肾功能不全效果确切，且可改善肾功能及骨代谢调节因子水平，增强免疫功能，降低不良反应发生率，更有利于骨功能的恢复，是一种安全、有效的治疗方案。
Abstract:
Objective To investigate the efficacy of bortezomib combined with dexamethasone and thalidomide in the treatment of multiple myeloma patients with renal insufficiency.Methods A total of 84 patients with multiple myeloma and renal insufficiency treated in our hospital from June 2019 to June 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 42 cases in each group. The control group was treated with cyclophosphamide, dexamethasone and thalidomide, while the observation group was treated with bortezomib, dexamethasone and thalidomide. The total effective rate, bone metabolism regulatory factor level, immune function index, renal function index and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.24%, which was higher than 83.33% of the control group (P<0.05). The receptor activator of unclear factor-κβ ligand (RANKL), tartrate-resistant acid phosphatase and alkaline phosphatase (TRACP-5b) in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). CD3+, CD4+, CD4+/CD8+ were higher than those before treatment, and the observation group was higher than the control group (P<0.05). Serum creatinine (Scr) and blood urea nitrogen (BUN) in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The incidence of adverse reactions in the observation group was 9.52%, which was lower than 21.43% in the control group (P<0.05).Conclusion Bortezomib combined with dexamethasone and thalidomide is effective in the treatment of multiple myeloma with renal insufficiency, which can improve renal function and bone metabolic regulator levels, enhance immune function, reduce the incidence of adverse reactions, and is more conducive to the recovery of bone function. It is a safe and effective treatment.

参考文献/References:

[1]张兵兵,王倩如,李妮.多发性骨髓瘤MAF缺失的临床特点及对预后的影响[J].山西医药杂志,2021,50(17):2553-2556.[2]李慧娉,高大.沙利度胺联合硼替佐米治疗多发性骨髓瘤的临床效果[J].热带医学杂志,2017,17(5):626-629.[3]张天琰,张鹂,吴秋慧,等.多发性骨髓瘤合并肾功能损害临床特征及其影响患者预后的相关因素[J].西部医学,2020,32(6):887-891.[4]王欢,赵真,张滔,等.硼替佐米联合地塞米松治疗老年多发性骨髓瘤的疗效及对免疫抑制因子、免疫细胞水平的影响[J].海南医学院学报,2017,23(2):232-235.[5]谢玮,庞缨,叶絮,等.PDD与PTD方案对多发性骨髓瘤患者的疗效及IL-6水平的影响比较[J].河北医学,2017,23(6):882-886.[6]多发性骨髓瘤肾损伤诊治专家共识协作组.多发性骨髓瘤肾损伤诊治专家共识[J].中华内科杂志,2017,56(11):871-875.[7]周宏伟,周晓燕,王志红,等.ABCD方案治疗复发/难治性多发性骨髓瘤的效果[J].中国医药导报,2018,15(23):86-89.[8]侯健,王文方.硼替佐米在多发性骨髓瘤伴肾功能损害患者的应用[J].肾脏病与透析肾移植杂志,2017,26(3):251-252.[9]赵晓梅,刘倩.皮下注射硼替佐米治疗多发性骨髓瘤流程改良与实践[J].中国全科医学,2017,20(2):128-129.[10]贾静,刘爱军,陈文明,等.RVD方案对新诊断多发性骨髓瘤患者缓解深度的研究[J].中国肿瘤临床,2019,46(14):734-738. [11]王红霞,白俊俊,裴智信,等.Venetoclax+HMAs联合剂量调整的HAG双诱导治疗复发难治性急性髓系白血病二例[J].中国临床案例成果数据库,2020,2(1):E025.[12]李青,胡赤丁,张长春,等.初诊IgG水平对IgG型多发性骨髓瘤患者初治完全缓解后复发的预测价值[J].中国实验血液学杂志,2021,29(6):1825-1830.[13]王光红,黄国军,李张维,等.多发性骨髓瘤的维持治疗方案[J].现代仪器与医疗,2017,23(4):125-127.[14]王懿铭,龙浩,阳丹,等.基于多种免疫细胞的细胞免疫治疗联合含硼替佐米的化疗方案治疗多发性骨髓瘤的临床观察[J].中国实验血液学杂志,2017,25(3):818-822.[15]王国苗,杨光忠,黄仲夏,等.中国多发性骨髓瘤患者接受来那度胺的多中心非干预性前瞻性观察研究[J].中华内科杂志,2017,56(7):500-506.[16]徐颖洁,黄红铭,徐瑞容.多发性骨髓瘤患者乙型肝炎病毒流行情况及相关预后分析[J].临床内科杂志,2017,34(9):622-624.[17]梁晨亮,赵振群,刘万林.OPG/RANKL/RANK信号通路在骨巨细胞瘤发病机制中的作用[J].中国组织工程研究,2020,24(23):3723-3729.[18]Rwigema JCM,Verma V,Lin L,et al.Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer[J].Cancer,2017,123(21):4244-4251.[19]陈钦玭.硼替佐米对多发性骨髓瘤患者临床疗效的影响[J].中国卫生标准管理,2021,17(10):37-38.[20]胡蓉,周立娟.硼替佐米联合地塞米松与沙利度胺对多发性骨髓瘤伴肾功能不全患者骨代谢调节因子、免疫功能及肾功能的影响[J].海南医学院学报,2017,23(22):3092-3095.

相似文献/References:

[1]王文迪,李小兵,刘光晶.N-乙酰半胱氨酸对烟雾吸入大鼠急性肺损伤的疗效观察[J].医学信息,2018,31(23):101.[doi:10.3969/j.issn.1006-1959.2018.23.027]
　WANG Wen-di,LI Xiao-bing,LIU Guang-jing.Experimental Study on the Therapeutic Effects of N-Acetylcysteine on Smoke Inhalation-induced Acute Lung Injury in Rats[J].Medical Information,2018,31(05):101.[doi:10.3969/j.issn.1006-1959.2018.23.027]
[2]赵宏玉,杨爱民.地塞米松对甲状腺切除术后自控镇痛恶心呕吐发生率的影响[J].医学信息,2018,31(24):101.[doi:10.3969/j.issn.1006-1959.2018.24.028]
　ZHAO Hong-yu,YANG Ai-min.Effect of Dexamethasone on the Incidence of Spontaneous Nausea and Vomiting after Thyroidectomy[J].Medical Information,2018,31(05):101.[doi:10.3969/j.issn.1006-1959.2018.24.028]
[3]艾 露.地塞米松联合庆大霉素在非哺乳期乳腺炎治疗中的应用[J].医学信息,2022,35(16):138.[doi:10.3969/j.issn.1006-1959.2022.16.035]
　AI Lu.Application of Dexamethasone Combined with Gentamicin in the Treatment of Non-lactating Mastitis[J].Medical Information,2022,35(05):138.[doi:10.3969/j.issn.1006-1959.2022.16.035]
[4]刘传志.小剂量秋水仙碱联合地塞米松对急性痛风性关节炎患者疼痛症状及不良反应的影响[J].医学信息,2022,35(17):126.[doi:10.3969/j.issn.1006-1959.2022.17.034]
　LIU Chuan-zhi.Effect of Low-dose colchicine Combined with Dexamethasone on Pain Symptoms and Adverse Reactions in Patients with Acute Gouty Arthritis[J].Medical Information,2022,35(05):126.[doi:10.3969/j.issn.1006-1959.2022.17.034]
[5]巴 琳,曾凡荣,郭忠宝.地塞米松联合切口阻滞和腹腔内局部麻醉对腹腔镜胆囊切除术后的镇痛效果[J].医学信息,2020,33(08):167.[doi:10.3969/j.issn.1006-1959.2020.08.056]
　BA Lin,ZENG Fan-rong,GUO Zhong-bao.Analgesic Effect of Dexamethasone Combined with Incision Block and Intraperitoneal Local Anesthesia After Laparoscopic Cholecystectomy[J].Medical Information,2020,33(05):167.[doi:10.3969/j.issn.1006-1959.2020.08.056]
[6]王启平,兰安宁,吴晓峰.低剂量地塞米松对乳腺癌化疗不良反应的影响[J].医学信息,2020,33(14):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
　WANG Qi-ping,LAN An-ning,WU Xiao-feng.Effect of Low-dose Dexamethasone on Adverse Reactions of Chemotherapy in Breast Cancer[J].Medical Information,2020,33(05):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
[7]彭 亮.地塞米松联合甘露醇治疗对急性重症脑血管病脑保护作用的临床观察[J].医学信息,2020,33(18):145.[doi:10.3969/j.issn.1006-1959.2020.18.048]
　PENG Liang.Clinical Observation of the Protective Effect of Dexamethasone Combined with Mannitol on the Cerebral Protection of Acute Severe Cerebrovascular Disease[J].Medical Information,2020,33(05):145.[doi:10.3969/j.issn.1006-1959.2020.18.048]
[8]吴 强.地塞米松在早期急诊中暑患者的应用效果[J].医学信息,2020,33(22):156.[doi:10.3969/j.issn.1006-1959.2020.22.045]
　WU Qiang.Application Effect of Dexamethasone in Early Emergency Patients with Heatstroke[J].Medical Information,2020,33(05):156.[doi:10.3969/j.issn.1006-1959.2020.22.045]
[9]张 芳,张丽平,包利红,等.基于CiteSpace的多发性骨髓瘤护理的可视化分析[J].医学信息,2023,36(04):73.[doi:10.3969/j.issn.1006-1959.2023.04.014]
　ZHANG Fang,ZHANG Li-ping,BAO Li-hong,et al.Visualization Analysis of Multiple Myeloma Nursing Research Based on CiteSpace[J].Medical Information,2023,36(05):73.[doi:10.3969/j.issn.1006-1959.2023.04.014]
[10]刘 倩,夏海龙.硼替佐米对多发性骨髓瘤患者认知功能的影响及与血清脑源性神经营养因子的相关性[J].医学信息,2023,36(07):105.[doi:10.3969/j.issn.1006-1959.2023.07.019]
　LIU Qian,XIA Hai-long.Effect of Bortezomib on Cognitive Function in Patients with Multiple Myeloma and its Correlation with Serum Brain-derived Neurotrophic Factor[J].Medical Information,2023,36(05):105.[doi:10.3969/j.issn.1006-1959.2023.07.019]
[11]金 英.硼替佐米治疗老年多发性骨髓瘤的效果[J].医学信息,2020,33(06):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]
　JIN Ying.Effect of Bortezomib in the Treatment of Elderly Multiple Myeloma[J].Medical Information,2020,33(05):146.[doi:10.3969/j.issn.1006-1959.2020.06.047]

更新日期/Last Update: 1900-01-01